CAD 0.09
(-10.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1.54 Million CAD | -70.96% |
2022 | 5.3 Million CAD | 172.93% |
2021 | 1.94 Million CAD | -26.71% |
2020 | 2.65 Million CAD | 237.26% |
2019 | 786.9 Thousand CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 783.68 Thousand CAD | 226.17% |
2024 Q1 | 240.26 Thousand CAD | -1.54% |
2023 Q4 | 244.02 Thousand CAD | -30.61% |
2023 Q2 | 159.53 Thousand CAD | -79.72% |
2023 FY | 1.54 Million CAD | -70.96% |
2023 Q3 | 351.68 Thousand CAD | 120.44% |
2023 Q1 | 786.49 Thousand CAD | -48.03% |
2022 Q2 | 2.11 Million CAD | 76.39% |
2022 Q4 | 1.51 Million CAD | 218.36% |
2022 FY | 5.3 Million CAD | 172.93% |
2022 Q1 | 1.2 Million CAD | 254.73% |
2022 Q3 | 475.32 Thousand CAD | -77.57% |
2021 Q1 | 675.26 Thousand CAD | -23.36% |
2021 FY | 1.94 Million CAD | -26.71% |
2021 Q4 | 338.61 Thousand CAD | -30.21% |
2021 Q3 | 485.16 Thousand CAD | 8.79% |
2021 Q2 | 445.95 Thousand CAD | -33.96% |
2020 Q4 | 881.05 Thousand CAD | 3300.05% |
2020 Q3 | 25.91 Thousand CAD | -97.9% |
2020 Q1 | 514.4 Thousand CAD | -21.68% |
2020 Q2 | 1.23 Million CAD | 139.6% |
2020 FY | 2.65 Million CAD | 237.26% |
2019 Q1 | - CAD | 0.0% |
2019 FY | 786.9 Thousand CAD | 0.0% |
2019 Q4 | 656.77 Thousand CAD | 404.7% |
2019 Q3 | 130.13 Thousand CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Aequus Pharmaceuticals Inc. | 254.89 Thousand CAD | -504.854% |
CanadaBis Capital Inc. | 22.22 Million CAD | 93.062% |
Decibel Cannabis Company Inc. | 115.95 Million CAD | 98.67% |
Delivra Health Brands Inc. | 12.37 Million CAD | 87.544% |
Entourage Health Corp. | 40.71 Million CAD | 96.213% |
Lifeist Wellness Inc. | 21.65 Million CAD | 92.882% |
Cannara Biotech Inc. | 57.26 Million CAD | 97.307% |
Medicure Inc. | 21.69 Million CAD | 92.893% |
Rubicon Organics Inc. | 40.11 Million CAD | 96.157% |
BioSyent Inc. | 31.59 Million CAD | 95.12% |
Voyageur Pharmaceuticals Ltd. | - CAD | -Infinity% |